Abbott Serlect NDA withdrawn; Lundbeck U.K. cohort study focusing on arrhythmias.
Executive Summary
ABBOTT SERLECT STUDY PLANS UNDECIDED AFTER NDA WITHDRAWAL Jan. 13, the company said. Abbott has said that it is conducting clinical trials examining the antipsychotic Serlect (sertindole) in patients failing risperidone (Janssen's Risperdal) and an open-label extension of trial M94-222. A study in Alzheimer's disease patients was planned in 1996. The Danish firm H. Lundbeck, which licenses sertindole to Abbott for the U.S., Canada, and Latin American territories, continues to market the drug as Serdolect in 12 European countries.
You may also be interested in...
Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup
Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011